Once Daily Vildagliptin 100 mg SR as safe, effective as Vildagliptin 50 mg twice daily add on to Metformin in Indian Diabetics: Discussion on Indian Study Results - Video

Published On 2022-07-26T12:45:24+05:30 | Updated On 3 May 2023 12:59 PM IST

Overview

Vildagliptin, an oral hypoglycemic agent, acts by inhibiting the dipeptidyl peptidase-4 enzyme. The clinical efficacy and safety of vildagliptin monotherapy or in combination with metformin have been demonstrated.

Vildagliptin 100 mg SR once daily or Vildagliptin 50mg twice daily when used along with metformin 1000 mg?

The question has recently been addressed in a recent research published in the National Journal of Physiology, Pharmacy and Pharmacology.

In conversation with Prof (Dr.) Nilanjan Sengupta, co-author of the study, from the Department of Endocrinology, Nil Ratan Sircar Medical College and Hospital, Kolkata, West Bengal, India, who discusses about the effectiveness and safety of vildagliptin 50 mg twice daily with vildagliptin 100 mg SR tablet once daily in Type 2 DM patients uncontrolled with metformin monotherapy.

Dr. Sengupta also provides insights about Diabetes mellitus management in Indian population.

Speakers

Dr. Nilanjan Sengupta

Prof Dr. Nilanjan Sengupta is an Endocrinologist and is currently working as a Professor & Head in the department of endocrinology at NRS Medical College. He has done his MD in internal medicine from the then University College of Medicine, Kolkata and DM in Endocrinology and Metabolism from IPGME&R and SSKM Hospital, Kolkata.

Dr. Nandita Mohan

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751